Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE)

It appears that there is no text provided for summarization. Please provide the document or information you would like me to summarize.

The CBD254-012 MAGPIE program seeks to develop Microphysiological systems (iMPS) for evaluating vaccines against high-consequence pathogens, addressing limitations of traditional in vitro/in vivo models. The objective is to create iMPS that can recapitulate known vaccine efficacy, differentiate between vaccines with variable efficacy, and predict immunogenicity of novel vaccine constructs. Phase I focuses on developing or refining an iMPS to demonstrate its ability to replicate immunogenicity and efficacy of an FDA-approved vaccine. Phase II will utilize the iMPS to predict the performance of new vaccines and develop Standard Operating Procedures (SOPs) and training materials. Phase III aims to broaden the iMPS's application for dose optimization, route of administration, and assessing off-target effects, ultimately reducing reliance on animal models. Dual-use applications include commercial biotechnology, pharmaceutical companies, and public health organizations for vaccine evaluation.

The CBD254-012 solicitation seeks to develop Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE) for vaccine evaluation against high-consequence pathogens. The objective is to create immune microphysiological systems (iMPS) that can model human immune responses in vitro, overcoming limitations of traditional vaccine development models. These iMPS should recapitulate vaccine immunogenicity and efficacy, differentiate between vaccine efficacies, and predict the immunogenicity of novel vaccine constructs. Phase I focuses on developing or refining an iMPS to replicate the response of an FDA-approved vaccine. Phase II aims to use the iMPS to predict the performance of novel vaccines and establish standardized operating procedures. Phase III will broaden the iMPS's application for dose optimization, booster frequency, and assessing off-target effects, reducing reliance on animal models. Dual-use applications extend to commercial biotechnology, pharmaceutical companies, academic research, and public health organizations for evaluating vaccine efficacy.

The CBD254-012 program,

The CBD254-012

The CBD254-012 solicitation seeks to develop Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE) for evaluating vaccines against high-consequence pathogens. The Defense Threat Reduction Agency (DTRA) aims to overcome limitations of traditional vaccine development by utilizing immune microphysiological systems (iMPS) that model human immune responses in vitro. These iMPS should recapitulate vaccine immunogenicity and efficacy, differentiate between vaccine efficacies, and predict novel vaccine construct immunogenicity. Phase I focuses on developing or refining an iMPS to demonstrate its capability in replicating the immunogenicity and efficacy of an FDA-approved vaccine. Phase II will leverage the iMPS to predict the performance of new vaccines against DoD pathogens, with deliverables including SOPs and training materials. Phase III aims to broaden the iMPS's application for dose optimization, booster frequency, and assessing off-target effects, ultimately reducing reliance on animal models. Dual-use applications extend to commercial biotechnology and pharmaceutical companies for vaccine evaluation.

The Defense Threat Reduction Agency (DTRA) seeks to develop Microphysiological Systems (MPS) to improve vaccine development against high-consequence pathogens. Current methods are slow and do not accurately predict human immune responses. The objective is to create immune MPS (iMPS) that can model human immune responses in vitro, accelerating medical countermeasure discovery. Phase I focuses on developing or refining an iMPS to recapitulate the immunogenicity and efficacy of an FDA-approved vaccine against a viral pathogen, with data standardized for comparison to clinical data. Phase II will leverage the iMPS to predict the performance of novel vaccine constructs, developing Standard Operating Procedures (SOPs) and training materials for reproducibility. Phase III aims to broaden the iMPS's application to evaluate key parameters like dose optimization and assess off-target effects using multi-organ MPS, reducing reliance on animal models. Dual-use applications extend to commercial biotechnology, pharmaceutical companies, academic research, and public health organizations for vaccine evaluation outside animal models.

The CBD254-012 "Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE)" program seeks to develop immune microphysiological systems (iMPS) for evaluating vaccines against high-consequence pathogens. Current vaccine development is hindered by slow and inadequate traditional models. The iMPS aims to bridge the gap between preclinical studies and clinical trials by accurately modeling human immune responses in vitro. Key objectives include recapitulating known vaccine immunogenicity and efficacy, differentiating vaccine efficacy, and predicting novel vaccine construct immunogenicity, with potential for optimizing dose, schedule, route, and predicting off-target effects. Phase I focuses on developing or refining an iMPS to replicate FDA-approved vaccine responses against a viral pathogen, standardizing data output for comparison with existing clinical data. Phase II will leverage the iMPS to predict the immunogenicity and efficacy of novel vaccines for the DoD, developing SOPs and training materials. Phase III expands the iMPS application to evaluate key parameters like administration route and dose optimization, and assess off-target effects in multi-organ systems. Dual-use applications include commercial biotechnology, pharmaceutical companies, academic research labs, and public health organizations for vaccine evaluation outside of animal models.

The CBD254-012

The CBD254-012

The CBD254-012

The CBD254-012 solicitation seeks to develop Microphysiological systems (MPS), specifically immune microphysiological systems (iMPS), for evaluating and developing vaccines against high-consequence pathogens. The objective is to create in vitro models that can accurately recapitulate human immune responses, accelerating the discovery and validation of medical countermeasures. Traditional in vitro and in vivo models are slow and often fail to translate to successful human clinical trials. The iMPS should be capable of assessing immunogenicity and efficacy, differentiating between vaccine efficacies, and predicting the immunogenicity of novel vaccine constructs. Phase I focuses on developing or refining an iMPS to replicate the immunogenicity and efficacy of an FDA-approved vaccine. Phase II aims to use the iMPS to predict the performance of new vaccines and develop Standard Operating Procedures. Phase III will broaden the iMPS's application for dose optimization, booster frequency, and assessing off-target effects, ultimately reducing reliance on animal models. Dual-use applications extend to commercial biotechnology, pharmaceutical companies, academic research, and public health organizations for vaccine evaluation.

The CBD254-012 solicitation seeks to develop Microphysiological systems (MPS) for assessing pretreatment immunogenicity and efficacy (MAGPIE) of vaccines against high-consequence pathogens. The objective is to create immune MPS (iMPS) that can evaluate and accelerate vaccine development by overcoming limitations of traditional in vitro and in vivo models. These iMPS should recapitulate known vaccine immunogenicity and efficacy, differentiate between vaccines with variable efficacy, and predict the immunogenicity of novel constructs. Phase I focuses on developing or refining an iMPS to replicate the immunogenicity and efficacy of an FDA-approved vaccine. Phase II aims to use the iMPS to predict the performance of novel vaccine constructs and establish standardized operating procedures. Phase III will broaden the iMPS's application for dose optimization, booster frequency, and assessing off-target effects, ultimately reducing reliance on animal models. Dual-use applications extend to commercial biotechnology, pharmaceutical companies, academic research, and public health organizations for evaluating vaccine immunogenicity and efficacy without animal models.

The CBD254-012 solicitation seeks to develop Microphysiological systems to Assess Pretreatment Immunogenicity and Efficacy (MAGPIE), specifically immune microphysiological systems (iMPS), for evaluating vaccines against high-consequence pathogens. The objective is to overcome limitations of traditional vaccine development models by creating iMPS that can recapitulate known vaccine responses, differentiate vaccine efficacy, and predict immunogenicity of novel constructs. Phase I focuses on developing or refining an iMPS to demonstrate its ability to replicate immunogenicity and efficacy of an FDA-approved vaccine. Phase II aims to use the iMPS to predict the performance of new vaccines, develop Standard Operating Procedures (SOPs), and create training materials. Phase III will broaden the iMPS's application for dose optimization, booster frequency, and assessing off-target effects, with dual-use applications for commercial biotechnology, pharmaceutical companies, academic research labs, and public health organizations to evaluate vaccine immunogenicity and efficacy outside of animal models.

The CBD254-012 solicitation seeks to develop Microphysiological Systems (MPS) to assess pretreatment immunogenicity and efficacy (MAGPIE) for vaccines against high-consequence pathogens. The objective is to create immune MPS (iMPS) that can model human immune responses in vitro, accelerating the discovery and validation of medical countermeasures. Traditional in vitro and in vivo models are slow and do not accurately reflect the human immune system, hindering rapid vaccine development for warfighter readiness. Phase I focuses on developing or refining an iMPS to recapitulate the immunogenicity and efficacy of an FDA-approved vaccine against a viral pathogen, with data standardized for comparison to existing clinical data. Phase II will leverage the iMPS to predict the immunogenicity and efficacy of novel vaccine constructs against DoD pathogens, developing Standard Operating Procedures (SOPs) and training materials for reproducibility. Phase III aims to broaden the iMPS's application in vaccine development, evaluating parameters like dose optimization and off-target effects, reducing reliance on animal models. Dual-use applications include commercial biotechnology, pharmaceutical companies, academic research labs, and public health organizations for vaccine evaluation outside of animal models.